Please try another search
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. Its Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. It is also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy. The company has a collaboration agreement with Merck Sharp & Dohme Corp. to study NOX-A12 combined with Keytruda and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. The company was formerly known as NOXXON Pharma N.V. and changed its name to TME Pharma N.V. in July 2022. TME Pharma N.V. was founded in 1997 and is based in Berlin, Germany.
Name | Age | Since | Title |
---|---|---|---|
Cornelis Alexander Izeboud | 52 | 2020 | Independent Member of Supervisory Board |
Jose Saro | - | 2021 | Chairman of Scientific Advisory Board |
Gabriela E. Chiorean | - | 2021 | Member of Scientific Advisory Board |
Eileen M. O’Reilly | - | 2021 | Member of Scientific Advisory Board |
Monika E. Hegi | - | 2022 | Member of Scientific Advisory Board |
Daniel Douglas Von Hoff | 75 | 2021 | Member of Scientific Advisory Board |
Thomas T. W. Seufferlein | - | 2021 | Member of Scientific Advisory Board |
Susan Coles | 57 | 2021 | Independent Deputy Chair of Supervisory Board |
Michael Lim | - | 2022 | Member of Scientific Advisory Board |
Maurizio PetitBon | 77 | 2016 | Independent Chairman of the Supervisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review